Collaborative models and IPO window are hot topics at BioPharm America™ 2014 program
Washington, DC; Carlsbad, CA and Boston, MA – May 20, 2014: The seventh annual BioPharm America™ international life science partnering conference will be held September 22–24 at Boston Marriott Copley Place in the center of Boston’s historic Back Bay. The event brings together industry thought leaders and high level executives in the biopharma dealmaking arena to collaborate on and discuss relevant trends and topics.
Several industry leaders commented on trends and topics that will be featured on the BioPharm America program this year.
"This IPO window has been open longer than any in biotech’s history; while it is unclear how long this cycle will continue, it has provided much needed growth capital to support a new generation of emerging biotech companies. In addition, the IPO route has provided a compelling alternative to M&A-driven liquidity. With pharma’s appetite for innovation continuing to be strong, I expect the interplay of the IPO and M&A markets to feature prominently as a hot topic at BioPharm America this year.” - Bruce L. Booth, Partner, Atlas Venture
“The dynamics of the research ecosystem are changing rapidly. At AstraZeneca we are creating a ‘porous’ research environment to actively engage external science. The recent launch of our Open Innovation website provides a broad range of collaborative and “co-creation” possibilities for academics. There will be ongoing discussion at BioPharm America regarding both open innovation and novel partnership paradigms.” - Kumar Srinivasan, VP, Scientific Partnering and Alliances, AstraZeneca
“The recent CoStim acquisition by Novartis turned the spotlight toward a particularly successful scientific collaboration between academic researchers and an entrepreneurial investor group that recognized the need for such assets within big pharma. This is a great demonstration of the new face of academic partnerships and the unique power of the Boston ecosystem.” - Michal Preminger, PhD, MBA, Executive Director, Office of Technology Development, Harvard Medical School.
Early academic collaboration is another focus of BioPharm America this year, as it will be a featured program topic and is the focus of an Academic Innovators presentation track.
“Academic research institutions are the nexus for early stage drug discovery collaborations opportunities with life science companies. We have the human genomics data to advance new targets, we have drug discovery capabilities, and we have the expertise. The game has changed and academia is the new innovation breeding ground.” - Leslie Molony, PhD, Senior Director, Business Development, Sanford-Burnham Medical Research Institute Office of Technology Management and Commercialization
More than 900 delegates representing 550 companies from 35 countries participated in BioPharm America 2013. Delegates in 2013 engaged in 2,950 one-to-one partnering meetings and identified 757 potential licensing opportunities.
BioPharm America is produced by EBD Group in collaboration with the Massachusetts Biotechnology Council (MassBio) to facilitate strategic collaborations with leading companies. One-to-one networking at BioPharm America™ is powered by partneringONE®, the leading conference networking solution for the life sciences.
Register before July 18, 2014 to save USD 200. MassBio members receive an additional USD 200 discount by adding the code ‘MassBio’ in the comments field of the online registration form.
Presenting companies should submit an application by June 30, 2014.
# # #
About BioPharm America 2014
BioPharm America is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®.
MassBio, a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation's oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services.